<DOC>
	<DOCNO>NCT02326935</DOCNO>
	<brief_summary>The intent clinical study answer question : 1 ) propose treatment safe 2 ) treatment effective improve disease pathology patient Multiple Sclerosis clinical outcome .</brief_summary>
	<brief_title>Multi-Center Study Safety Adipose Derived Mesenchymal Stem Cells Treatment Multiple Sclerosis</brief_title>
	<detailed_description>This open-label , non-randomized multi-center patient sponsor study ADSC implantation use IV delivery system . The study provide therapy 100 qualified patient match inclusion/exclusion criterion , agree follow program provide sign consent procedure . The treatment combination ( ) general detoxification , ( b ) lymphatic massage/drainage , ( c ) therapeutic massage , reflexology acupuncture ( ) cellular infusion therapy cell deploy via IV injection two treatment 60 minute five ( 5 ) day treatment period . Follow-up data base upon MSIS-29 , modify SF-36 standard complication questionnaire collect 3 , 6 annually post treatment patient ' local physician report back sponsor log HIPPA-compliant outcome database . Additional safety data , base upon standard complication questionnaire collect via survey patient interval 3 6 month annually minimum five ( 5 ) year .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Confirmed Diagnosis MS Aged 18 65 year . Duration disease : &gt; 5 year Signed , write informed consent willing able comply study visit accord protocol full study period Physically , mentally legally capable international travel treatment Patients suffer significant cardiac , renal hepatic failure disease may risk patient interfere ability interpret result Patient active chronic infection No lifethreatening organ dysfunction . Pregnancy risk pregnancy . Severe physical limitation disability Patients seropositive HIV1 , HIV2 , Hepatitis B Surface Antigen , Hepatitis C Patients unable give write informed consent accordance research ethic board guideline Treatment immunosuppressive therapy within 3 month prior randomization Current treatment investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>MS</keyword>
	<keyword>Multiple Sclerosis , Relapsing-Remitting</keyword>
	<keyword>Multiple Sclerosis , Chronic Progressive</keyword>
	<keyword>Myelitis</keyword>
</DOC>